STATCenter·
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Read at STAT →
Health · 1 sources covering this
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/5dd9794200533e082eb42790e17ee49925dd525b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study"></iframe>